Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MPL-Adjuvanted recombinant hepatitis B vaccine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | - |
| Group B | ACTIVE_COMPARATOR | - |
| Group C | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MPL-Adjuvanted recombinant hepatitis B vaccine | BIOLOGICAL | Intramuscular injection, 2 or 3 doses, 2 different formulations |
| Engerix™-B | BIOLOGICAL | Intramuscular injection, 2 or 3 doses |
Inclusion Criteria: * Between 18 and 40 years old. * Written informed consent will have been obtained from the subjects. * Good physical condition as established by physical examination and history taking at the time of entry. * Female participants will avoid becoming pregnant during the study peri...
Top 6 of 8 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Gilead Sciences, Inc. | GILD | 3 | PHASE3 | Viread, Tenofovir alafenamide |
| Vir Biotechnology, Inc. | VIR | 6 | PHASE3 | Tobevibart, Elebsiran |
| Bausch Health Companies Inc. | BHC | 1 | PHASE3 | Larsucosterol |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Daplusiran/Tomligisiran, Bepirovirsen |
| Aligos Therapeutics, Inc. | ALGS | 1 | PHASE2 | ALG-000184 |
| Precision BioSciences, Inc. | DTIL | 2 | PHASE1 | PBGENE-HBV |
It is an investigational hepatitis B vaccine developed by GSK plc that combines a recombinant hepatitis B antigen with the MPL adjuvant. It is designed to prevent hepatitis B infection and is being studied in a Phase 3 clinical program.
It is being developed for the prevention of hepatitis B, an infectious disease of the liver. The vaccine is intended to induce protective immunity against hepatitis B virus and is in Phase 3 clinical development.
GSK plc, which trades under the ticker GSK, is the developer of the MPL-Adjuvanted recombinant hepatitis B vaccine. The company is responsible for the clinical development program for this vaccine candidate.
MPL-Adjuvanted recombinant hepatitis B vaccine is in Phase 3 clinical development. It is an investigational vaccine and has not been approved by the FDA. The Phase 3 trial has been completed.
The vaccine has been studied in one completed Phase 3 trial, NCT00698087, titled Comparison of Safety, Immuno- and Reactogenicity of MPL-Adjuvanted Recombinant Hepatitis B Vaccine to That of Engerix-B. The trial enrolled 60 healthy adult volunteers in Austria and was randomized, double-blind, and active-controlled.